Kiniksa Pharmaceuticals International (KNSA) Preferred Stock Liabilities (2017 - 2018)
Kiniksa Pharmaceuticals International (KNSA) posted Preferred Stock Liabilities of $310.6 million for Q1 2018, up 159.32% on a QoQ basis from $119.8 million in Q4 2017.
Kiniksa Pharmaceuticals International (KNSA) Preferred Stock Liabilities (2017 - 2018) Analysis & Trends
Kiniksa Pharmaceuticals International's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $310.6 million for Q1 2018.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $310.6 million in Q1 2018, while the trailing twelve-month figure through Mar 2018 was $310.6 million (changed N/A YoY) and the FY2017 annual result came in at $119.8 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $310.6 million for Q1 2018 at Kiniksa Pharmaceuticals International, up from $119.8 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $310.6 million in Q1 2018 and bottomed at $119.8 million in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Kiniksa Pharmaceuticals International | 4.82 Bn | 4.36 Bn | 193.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2018 | 310.59 Mn |
| Dec 31, 2017 | 119.77 Mn |